---
title: "10:02 ETShareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291158080.md"
description: "Ademi LLP is investigating Theravance Biopharma (NASDAQ: TBPH) regarding its transaction with Zymeworks, alleging potential breaches of fiduciary duty by the board. The deal offers shareholders $17.00 per share plus contingent value rights. Ademi questions if this provides a fair price and criticizes change-of-control arrangements that penalize competing bids, aiming to determine if directors are fulfilling their duties to all public shareholders."
datetime: "2026-06-29T14:03:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291158080.md)
  - [en](https://longbridge.com/en/news/291158080.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291158080.md)
---

# 10:02 ETShareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders

, /PRNewswire/ -- Ademi LLP is investigating Theravance Biopharma (NASDAQ: TBPH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Zymeworks.

Click here to learn how to join our investigation and obtain additional information or contact us at \[email protected\] or toll-free: 866-264-3995. There is no cost or obligation to you.

Theravance Biopharma shareholders will receive $17.00 per share in cash, representing an equity value of approximately $929 million. Theravance Biopharma shareholders will also receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture, or other monetization of ampreloxetine over the next ten years. Zymeworks will retain the remaining 20% of such proceeds.  
Theravance Biopharma insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Theravance Biopharma by imposing a significant penalty if Theravance Biopharma accepts a competing bid. We are investigating the conduct of the Theravance Biopharma board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP  
Guri Ademi  
Toll Free: (866) 264-3995  
Fax: (414) 482-8001

SOURCE Ademi LLP

### Related Stocks

- [TBPH.US](https://longbridge.com/en/quote/TBPH.US.md)
- [ZYME.US](https://longbridge.com/en/quote/ZYME.US.md)

## Related News & Research

- [Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH](https://longbridge.com/en/news/295997292.md)
- [TBPH: Definitive acquisition agreement, strong YUPELRI® growth, and major cost reductions in Q2 2026](https://longbridge.com/en/news/295409943.md)
- [How Zymeworks’ Bigger Loss, Buyback and Milestones Pivot At Zymeworks (ZYME) Has Changed Its Investment Story](https://longbridge.com/en/news/296173401.md)
- [Zymeworks (ZYME) Back In Focus After Q2 Loss, Buyback, And Pipeline Events Raised Valuation Questions](https://longbridge.com/en/news/296030517.md)
- [Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | TBPH Stock News](https://longbridge.com/en/news/295408037.md)